

AMENDMENT AND RESPONSE TO OFFICE ACTION

Amendment

In the Claims

1. (currently amended) A drug delivery composition comprising a biodegradable, aliphatic poly(ester-anhydride) copolymer comprising random ester bonds along the polymer chain polyanhydride backbone and a biologically active agent, ~~wherein the copolymer comprises anhydride monomers, oligomers, polymers, or combinations thereof, separated by the random ester bonds.~~

2. (original) The composition of claim 1, wherein the biologically active agent is selected from the group consisting of small drug molecules, peptides and proteins, DNA and DNA complexes with cationic molecules.

3. (original) The composition of claim 1, wherein the composition is in a form suitable for administration by injection.

4. (canceled)

5. (canceled)

6. (previously presented) The composition of claim 1, wherein the poly(ester-anhydride) comprises one or more monomers derived from a hydroxy acid or dicarboxylic acid selected from the group consisting of C4 to C 22 linear alkane dicarboxylic acids, dimer erucic acid, dimer oleic acid, ricinoleic acid, non-linear fatty acid-esters of ricinoleic acid, oligomers or polymers of hydroxyl acids, O-esters and carbonates of ricinoleic acid, oligo(hydroalkanoic

AMENDMENT AND RESPONSE TO OFFICE ACTION

acid)-O-esters and carbonates of ricinoleic acid, hydroxyl-acid terminated oligomers containing a ricinoleic acid terminal, and mixtures thereof.

7. (previously presented) The composition of claim 6, wherein the hydroxy acid is an oligomer or polymer of hydroxy acids.

8. (previously presented) The composition of claim 26, wherein the polymer is prepared from purified ricinoleic acid, wherein ricinoleic acid comprises at least 90% by weight of the polymer.

9. (original) The composition of claim 1, wherein the biologically active agent is encapsulated in microparticles or nanoparticles.

10. (original) The composition of claim 2, wherein the biologically active agent is selected from the group consisting of the group consisting of antibacterial, anti-inflammatory and anticancer agents, antidepressants, analgesics and local anesthetics.

Claims 11-14. Canceled

15. (previously presented) The composition of claim 6, wherein the poly(ester anhydride) copolymer comprises monomers derived from a dicarboxylic acid selected from the group consisting of dodecanedioic acid and sebacic acid and comonomers derived from ricinoleic acid, non-linear fatty acid-esters of ricinoleic acid, oligomers or polymers of hydroxyl acids, O-esters and carbonates of ricinoleic acid, oligo(hydroalkanoic acid)-O-esters and carbonates of ricinoleic acid, hydroxyl-acid terminated oligomers containing a ricinoleic acid terminal, and mixtures thereof.

AMENDMENT AND RESPONSE TO OFFICE ACTION

16. (previously presented) The composition of claim 15, wherein the polymer is terminated with a fatty acid selected from the group consisting of ricinoleic acid, oleic acid, linoleic acid, and linolenic acid.

17. (currently amended) A drug delivery composition comprising a biodegradable poly(ester-anhydride) copolymer comprising random ester bonds along the polymer chain polyanhydride backbone and a biologically active agent, ~~wherein the poly(ester-anhydride) comprises anhydride monomers, oligomers, polymers, or combinations thereof, separated by the random ester bonds~~ wherein the poly(ester anhydride) comprises monomers derived from ricinoleic acid and sebacic acid.

18. (previously presented) The composition of claim 17, the polymer is a copolymer of sebacic acid and ricinoleic acid.

19. (previously presented) The drug delivery composition of claim 18, wherein the ratio of monomers derived from ricinoleic acid to monomers derived from sebacic acid is 8:2 or 7:3.

20. (previously presented) The composition of claim 17, wherein the biologically active agent is selected from the group consisting of small drug molecules, peptides and proteins, DNA and DNA complexes with cationic molecules.

21. (previously presented) The composition of claim 17, wherein the composition is in a form suitable for administration by injection.

AMENDMENT AND RESPONSE TO OFFICE ACTION

22. (previously presented) The composition of claim 17, wherein the polymer is prepared from purified ricinoleic acid, wherein ricinoleic acid comprises at least 90% by weight of the polymer.

23. (previously presented) The composition of claim 17, wherein the biologically active agent is encapsulated in microparticles or nanoparticles.

24. (previously presented) The composition of claim 20, wherein the biologically active agent is selected from the group consisting of the group consisting of antibacterial, anti-inflammatory and anticancer agents, antidepressants, analgesics and local anesthetics.

25. (previously presented) The composition of claim 7, wherein the hydroxy acid is selected from the group consisting of lactic acid, glycolic acid, hydroxybutyric acid, hydroxycaproic acid, hydroxybenzoic acid, mucic acid, tartaric acid, pentahydroxycyclohexane carboxylic acid and combinations thereof.

26. (previously presented) The composition of claim 6, wherein the poly(ester anhydride) comprises monomers, oligomers, polymers, or combinations thereof derived from sebacic acid and monomers derived from ricinoleic acid.

27. (previously presented) The composition of claim 26, wherein the poly(ester anhydride) is formed from monomers, oligomers, polymers, or combinations thereof derived from sebacic acid and monomers derived from ricinoleic acid.